von Willebrand Factor, ADAMTS13 Activity, and Decline in Kidney Function: A Population-Based Cohort Study

Area of Science:

• Nephrology
• Hematology
• Cardiovascular Research

Background:

• Altered levels of von Willebrand factor (vWF) and ADAMTS13 are implicated in thrombosis and impaired kidney microcirculation.
• Investigating the vWF:ADAMTS13 ratio's association with kidney function decline is crucial for understanding kidney disease.
• The Rotterdam Study provides a population-based cohort for this investigation.

Purpose of the Study:

• To examine the association between the serum vWF:ADAMTS13 ratio and the decline in kidney function.
• To determine if this ratio predicts the progression of chronic kidney disease.

Main Methods:

• A prospective cohort study involving 2,479 individuals from the population-based Rotterdam Study.
• Serum levels of vWF, ADAMTS13, and their ratio were measured.
• Annual decline in estimated glomerular filtration rate (eGFR), halving of eGFR, and new-onset eGFR < 60 mL/min/1.73m² were assessed over a median follow-up of 11 years.

Main Results:

• A higher vWF:ADAMTS13 ratio was significantly associated with a steeper annual decline in eGFR.
• Elevated vWF:ADAMTS13 ratio increased the risk for new-onset eGFR < 60 mL/min/1.73m² and halving of eGFR.
• These associations remained consistent after adjusting for cardiovascular risk factors and blood group.

Conclusions:

• The study demonstrates that a higher vWF:ADAMTS13 ratio is associated with declining kidney function in a population-based cohort.
• This finding suggests that elevated prothrombotic factors contribute to the development and progression of kidney disease.
• Limitations include a single measurement of vWF and ADAMTS13 and lack of albuminuria data.